The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

Table 2 Baseline characteristics for subjects who had available information on apolipoprotein E genotype

	Total (n = 274)	APOE ϵ4 carriers (n = 129)	APOE ϵ4 noncarriers (n = 145)	P value^a
Age	68 (8.9)	69 (8.8)	68 (8.9)	0.76
Sex, female	48	53	44	0.16
Hypertension	44	36	50	0.02
Diabetes	8	8	9	0.72
Cholesterol	34	30	38	0.18
Smoking	8	6	10	0.29
ADAS-Cog/MCI	14 (7.0)	16 (7.4)	13 (6.2)	0.00
Whole brain (ml)	1,088 (122)	1,083 (110)	1,092 (132)	0.54
Hippocampal volume (ml)	5.91 (0.85)	5.83 (0.90)	5.98 (0.83)	0.17

Data presented as means (standard deviation) or percentages. ADAS-Cog, Alzheimer’s Disease Assessment Scale – cognitive subscale; APOE, apolipoprotein E; MCI, mild cognitive impairment. ^aP values for differences in means or percentages between patients treated with placebo and those treated with galantamine.